• NovImmune

  Led · Series B · Dec 2010

  Novimmune is a privately held Swiss biopharmaceutical company headquartered in Geneva that discovers and develops antibody-based drugs. Its pipeline targets inflammatory and rare diseases, immune-related disorders, and cancer, including therapies aimed at conditions such as Hemophagocytic Lymphohistiocytosis (HLH). The company focuses on targeted antibody-based therapies as its core product approach. Novimmune said it plans to further develop novel medicines to provide improved treatment options for patients with rare and devastating diseases, autoimmune and inflammatory diseases, and cancer. Financially, the company completed a CHF30 million (US$29.8 million) funding round driven by major commitments from lead investors and broad participation from existing shareholders. Eduard Holdener is Chairman and CEO. Novimmune is focused on creating medicines for patients in need, emphasizing next-generation antibody therapeutics and orphan-disease applications. The company advances clinical-stage candidates including NI-0501 (for a life‑threatening orphan disease) and NI-0101 (a first‑in‑class anti‑TLR4 antibody). Novimmune is developing a kappa/lambda body™ bispecific drug platform, including approaches to selectively inhibit CD47 on cancer cells. The company plans to develop and commercialize NI-0501 with its own resources while pursuing partnerships to exploit larger market opportunities for other programs. Novimmune recently strengthened its financial position by closing a CHF 60 million Series B financing. The company is based in Geneva and states an intention to bring medicines to market for orphan disease indications. NovImmune focuses on discovering and developing therapeutic monoclonal antibodies (mAbs) for inflammatory diseases and immune-related disorders. The company has generated seven proprietary mAbs and maintains a pipeline balanced between preclinical and clinical compounds. Three compounds are currently in clinical development, with the most advanced in Phase II. NovImmune has developed a proprietary bispecific antibody generation platform named kappa-lambdabodies™. Management intends to use recent financing to generate proof-of-concept data for at least two compounds, expand the number of partnerships, and complete validation of the kappa-lambdabodies™ platform. The company is headquartered in Geneva, Switzerland.

No current team members are available.